Publication date: Jul 09, 2025
Optimizing a human monoclonal antibody for better neutralization of SARS-CoV-2. Using structural modeling and targeted mutation, the researchers modified a single amino acid in the antibodys structure to improve its flexibility and binding performance. In lab experiments, the virus was still able to mutate around one of the modified versions, albeit at a cost to its fitness. Yet the reality is that millions of individuals worldwide are sufficiently immunocompromised that they cannot benefit from the protection conferred by COVID-19 vaccines. For these individuals, monoclonal antibodies are an essential tool to prevent infection.
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Guanosine |
| pathway | KEGG | Hepatitis C |
| disease | MESH | hepatitis C |
| disease | MESH | influenza |
| disease | IDO | protein |
| disease | MESH | infection |
| disease | MESH | emergency |
| disease | MESH | COVID-19 |
| disease | MESH | AIDS |
| drug | DRUGBANK | Tropicamide |
Original Article
(Visited 2 times, 1 visits today)